CL2010001426A1 - Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. - Google Patents
Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.Info
- Publication number
- CL2010001426A1 CL2010001426A1 CL2010001426A CL2010001426A CL2010001426A1 CL 2010001426 A1 CL2010001426 A1 CL 2010001426A1 CL 2010001426 A CL2010001426 A CL 2010001426A CL 2010001426 A CL2010001426 A CL 2010001426A CL 2010001426 A1 CL2010001426 A1 CL 2010001426A1
- Authority
- CL
- Chile
- Prior art keywords
- useful
- treatment
- pharmaceutical composition
- oncological
- tricycles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Abstract
Compuestos derivados tricíclicos; composición farmacéutica, útil en el tratamiento de condiciones inmunológicas y oncológicas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13160208P | 2008-06-10 | 2008-06-10 | |
US13159908P | 2008-06-10 | 2008-06-10 | |
US19015908P | 2008-08-26 | 2008-08-26 | |
US20106408P | 2008-12-05 | 2008-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2010001426A1 true CL2010001426A1 (es) | 2011-07-15 |
Family
ID=41415363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2010001426A CL2010001426A1 (es) | 2008-06-10 | 2010-12-10 | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. |
Country Status (37)
Country | Link |
---|---|
US (5) | US8962629B2 (es) |
EP (2) | EP3031324A3 (es) |
JP (2) | JP5748659B2 (es) |
KR (2) | KR20110017431A (es) |
CN (2) | CN102118968A (es) |
AR (1) | AR072086A1 (es) |
AU (1) | AU2009257602B2 (es) |
BR (1) | BRPI0915374B1 (es) |
CA (2) | CA2727032C (es) |
CL (1) | CL2010001426A1 (es) |
CO (1) | CO6382083A2 (es) |
CR (1) | CR20160007A (es) |
CY (1) | CY1117165T1 (es) |
DK (1) | DK2299821T3 (es) |
DO (2) | DOP2010000382A (es) |
EC (1) | ECSP10010657A (es) |
ES (1) | ES2559403T3 (es) |
HK (1) | HK1155617A1 (es) |
HR (1) | HRP20160098T1 (es) |
HU (1) | HUE028347T2 (es) |
IL (1) | IL209434A0 (es) |
ME (1) | ME02340B (es) |
MX (1) | MX2010013557A (es) |
MY (1) | MY161369A (es) |
NO (1) | NO20101688A1 (es) |
NZ (1) | NZ623922A (es) |
PE (2) | PE20140407A1 (es) |
PL (1) | PL2299821T3 (es) |
PT (1) | PT2299821E (es) |
RS (1) | RS54560B1 (es) |
RU (2) | RU2015105591A (es) |
SI (1) | SI2299821T1 (es) |
TW (3) | TW201612182A (es) |
UA (1) | UA106045C2 (es) |
UY (1) | UY31881A (es) |
WO (1) | WO2009152133A1 (es) |
ZA (1) | ZA201008562B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201612182A (en) | 2008-06-10 | 2016-04-01 | Abbvie Inc | Novel tricyclic compounds |
US20120034250A1 (en) | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
WO2010123919A2 (en) | 2009-04-20 | 2010-10-28 | Auspex Pharmaceuticals, Llc | Piperidine inhibitors of janus kinase 3 |
WO2011011594A2 (en) * | 2009-07-23 | 2011-01-27 | Shriners Hospitals For Children | Intracellular toll-like receptors pathways and axonal degeneration |
US8361962B2 (en) * | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
KR101481872B1 (ko) | 2009-09-10 | 2015-01-12 | 에프. 호프만-라 로슈 아게 | Jak의 억제제 |
WO2011033053A1 (en) | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Macrocyclic inhibitors of jak |
ES2759949T3 (es) | 2009-10-29 | 2020-05-12 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos |
AU2010326030A1 (en) * | 2009-12-01 | 2012-06-07 | Abbvie Inc. | Novel tricyclic compounds |
CN102711476B (zh) * | 2009-12-01 | 2014-12-03 | Abbvie公司 | 新的三环化合物 |
WO2011082267A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrazine compounds |
EP2523957A1 (en) * | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
US8637529B2 (en) | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
DE102011106849A1 (de) | 2010-12-15 | 2012-06-21 | Merck Patent Gmbh | Verfahren zur Synthese N-N verknüpfter und um die N-N Bindung rotationsgehinderter bis-N-heterocyclische Carbene und deren Einsatz als Liganden für Metallkomplexe |
TW201309639A (zh) * | 2011-02-17 | 2013-03-01 | Lg Life Sciences Ltd | 作為gpr119促效劑之肟衍生物 |
US9115133B2 (en) * | 2011-03-22 | 2015-08-25 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
CA2831680C (en) * | 2011-04-21 | 2020-04-21 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
US20120330012A1 (en) * | 2011-04-29 | 2012-12-27 | Abbott Laboratories | Novel Tricyclic Compounds |
AR086113A1 (es) | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
WO2013007768A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
MX365311B (es) * | 2011-08-12 | 2019-05-29 | Nissan Chemical Ind Ltd | Compuestos heterocíclicos tricíclicos inhibidores de jak. |
CN104640843A (zh) | 2012-07-19 | 2015-05-20 | 大日本住友制药株式会社 | 1-(环烷基羰基)脯氨酸衍生物 |
EP2895489B1 (en) | 2012-09-17 | 2017-10-18 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10a |
US9593115B2 (en) * | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
CN102961382B (zh) * | 2012-11-28 | 2014-07-16 | 玉林师范学院 | 一种骨肉瘤细胞抑制剂及制备方法 |
JP6248948B2 (ja) | 2013-02-08 | 2017-12-20 | 日産化学工業株式会社 | 3環性ピロロピリジン化合物及びjak阻害剤 |
JP2016135742A (ja) * | 2013-03-29 | 2016-07-28 | 日本農薬株式会社 | 縮合複素環化合物又はその塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法 |
WO2014169473A1 (en) * | 2013-04-19 | 2014-10-23 | Abbvie Inc. | 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
CN103694168B (zh) * | 2013-12-05 | 2015-08-19 | 贵州威顿晶磷电子材料股份有限公司 | 一种6-氯-4-三氟甲基-3-氰基吡啶的制备方法 |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9890165B2 (en) | 2014-05-14 | 2018-02-13 | Nissan Chemical Industries, Ltd. | Tricyclic compound and JAK inhibitor |
JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
CN106794126A (zh) * | 2014-08-27 | 2017-05-31 | 艾伯维公司 | 局部配制品 |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
JP6791873B2 (ja) | 2015-04-02 | 2020-11-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | イミダゾロニルキノリンおよびatmキナーゼ阻害剤としてのその使用 |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP3362455A1 (en) | 2015-10-16 | 2018-08-22 | AbbVie Inc. | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP3712153B1 (en) | 2016-02-24 | 2021-12-01 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors |
EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
AU2017377069B2 (en) | 2016-12-16 | 2020-07-23 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
CA3052873A1 (en) | 2017-03-09 | 2018-09-13 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
US11254668B2 (en) | 2017-08-14 | 2022-02-22 | Pfizer Inc. | Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives |
BR112020005174A2 (pt) | 2017-09-14 | 2020-11-10 | Daiichi Sankyo Company,Limited | composto que possui estrutura cíclica |
WO2019100008A1 (en) * | 2017-11-20 | 2019-05-23 | Georgetown University | Treatments and methods for controlling hypertension |
CN113039277A (zh) | 2018-01-05 | 2021-06-25 | 渥太华医院研究所 | 修饰的正痘病毒载体 |
TW201940483A (zh) | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶2介導的傳訊之抑制劑 |
CN110294761B (zh) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
CN110872250B (zh) * | 2018-08-31 | 2023-01-10 | 苏州鹏旭医药科技有限公司 | 两种化合物及其制备方法和在合成乌西替尼中的用途 |
AU2019372677A1 (en) | 2018-11-01 | 2021-05-13 | Lynk Pharmaceuticals Co. Ltd. | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
CN109369659B (zh) * | 2018-12-06 | 2020-10-27 | 浙江师范大学 | 一种jak抑制剂的合成方法 |
JP7371221B2 (ja) * | 2019-07-26 | 2023-10-30 | 珠海宇繁生物科技有限責任公司 | Irak4キナーゼ阻害剤及びその調製方法 |
CN110483514B (zh) * | 2019-09-16 | 2022-06-14 | 启元生物(杭州)有限公司 | 一种氰基取代的环肼衍生物及其应用 |
CN113912535B (zh) * | 2020-07-07 | 2023-04-07 | 新发药业有限公司 | 一种6-氯-4-三氟甲基-3-氰基吡啶的制备方法 |
KR20230038229A (ko) | 2020-07-08 | 2023-03-17 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도 |
EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
CN112028888B (zh) * | 2020-09-11 | 2021-08-20 | 中国药科大学 | 一种化合物及其制备方法和用途 |
US20240108633A1 (en) * | 2020-12-29 | 2024-04-04 | Onquality Pharmaceuticals China Ltd. | Method for preventing or treating disease or condition associated with antitumor agent |
CN113332298A (zh) * | 2021-05-27 | 2021-09-03 | 成都医学院 | 米诺环素作为酪氨酸激酶抑制剂的新用途 |
CN113603693B (zh) * | 2021-07-13 | 2022-08-26 | 陕西丽彩药业有限公司 | 一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法 |
WO2023194842A1 (en) | 2022-04-05 | 2023-10-12 | Unichem Laboratories Limited | Substituted tricyclic compounds and their use in rheumatoid arthritis |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1376A (en) * | 1839-10-18 | Wateb-wheel | ||
GB716327A (en) | 1951-09-05 | 1954-10-06 | Ici Ltd | New heterocyclic compounds |
US3663559A (en) * | 1969-12-03 | 1972-05-16 | Union Carbide Corp | Preparation of oxo-furo-pyridines from furylvinyl isocyanates |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4053474A (en) * | 1976-04-21 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
ATE195739T1 (de) | 1989-10-20 | 2000-09-15 | Kyowa Hakko Kogyo Kk | Kondensierte purinderivate |
ATE271064T1 (de) | 1990-01-11 | 2004-07-15 | Isis Pharmaceuticals Inc | Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression |
US6262241B1 (en) * | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
AU668864B2 (en) | 1991-03-18 | 1996-05-23 | Centocor Inc. | Chimeric antibodies specific for human tumor necrosis factor |
KR100207360B1 (ko) | 1991-06-14 | 1999-07-15 | 돈 더블유. 슈미츠 | 이미다조[1,5,-a]퀸옥살린 |
US5212310A (en) * | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
US5266698A (en) * | 1992-04-30 | 1993-11-30 | Neurogen Corporation | Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands |
US5306819A (en) | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP0686157A1 (en) | 1993-02-26 | 1995-12-13 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
US5733905A (en) * | 1993-07-29 | 1998-03-31 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
US5736540A (en) * | 1993-07-29 | 1998-04-07 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5547975A (en) | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
RU2158127C2 (ru) | 1994-12-23 | 2000-10-27 | Варнер-Ламберт Компани | Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция |
US5521173A (en) * | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
US5753648A (en) * | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5763137A (en) * | 1995-08-04 | 1998-06-09 | Agfa-Gevaert, N.V. | Method for making a lithographic printing plate |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
AU756838B2 (en) * | 1998-03-04 | 2003-01-23 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
TWI271406B (en) * | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
MXPA03001186A (es) * | 2000-08-07 | 2004-04-20 | Neurogen Corp | Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa). |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0124299D0 (en) * | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
ATE353013T1 (de) * | 2002-02-19 | 2007-02-15 | Pfizer Italia Srl | Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel |
TW200400034A (en) * | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
US7169926B1 (en) * | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CA2566158A1 (en) * | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
AR049300A1 (es) | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
DE502005008916D1 (de) | 2004-07-23 | 2010-03-11 | Medicines Co Leipzig Gmbh | Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung |
AU2006205850A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as cell cycle kinase inhibitors |
US7947695B2 (en) * | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
EP1863813A2 (en) * | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods |
US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
US7593820B2 (en) * | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
JP5071374B2 (ja) * | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
CA2619049A1 (en) * | 2005-08-16 | 2007-02-22 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
US20090240055A1 (en) | 2005-09-23 | 2009-09-24 | Krepski Larry R | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof |
ES2390135T3 (es) | 2005-11-22 | 2012-11-06 | Merck Sharp & Dohme Corp. | Compuestos tricíclicos útiles como inhibidores de quinasas |
JP5512975B2 (ja) * | 2005-12-29 | 2014-06-04 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬 |
JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
EP2068869A4 (en) | 2006-10-06 | 2011-05-25 | Abbott Lab | NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE |
CA2675288A1 (en) | 2007-01-12 | 2008-07-17 | Astellas Pharma Inc. | Condensed pyridine compound |
US20100190787A1 (en) | 2007-01-30 | 2010-07-29 | Srinivas Rao Kasibhatla | Modulators of Mitotic Kinases |
WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
US7723343B2 (en) | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
EP2247592B1 (en) * | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
JP5529049B2 (ja) * | 2008-02-25 | 2014-06-25 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼ阻害剤 |
WO2009106445A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
WO2009108827A1 (en) | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
TW201612182A (en) | 2008-06-10 | 2016-04-01 | Abbvie Inc | Novel tricyclic compounds |
JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス, インコーポレイテッド | Cdkモジュレーター |
US20120034250A1 (en) * | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
US8361962B2 (en) * | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
CN102711476B (zh) * | 2009-12-01 | 2014-12-03 | Abbvie公司 | 新的三环化合物 |
AU2010326030A1 (en) | 2009-12-01 | 2012-06-07 | Abbvie Inc. | Novel tricyclic compounds |
US8637529B2 (en) * | 2010-06-11 | 2014-01-28 | AbbYie Inc. | Pyrazolo[3,4-d]pyrimidine compounds |
US20120330012A1 (en) * | 2011-04-29 | 2012-12-27 | Abbott Laboratories | Novel Tricyclic Compounds |
US20130072470A1 (en) * | 2011-09-21 | 2013-03-21 | Abbvie Inc. | Novel tricyclic compounds |
-
2009
- 2009-06-09 TW TW104143241A patent/TW201612182A/zh unknown
- 2009-06-09 TW TW103118323A patent/TWI527819B/zh active
- 2009-06-09 EP EP15192686.2A patent/EP3031324A3/en not_active Withdrawn
- 2009-06-09 MX MX2010013557A patent/MX2010013557A/es active IP Right Grant
- 2009-06-09 CA CA2727032A patent/CA2727032C/en active Active
- 2009-06-09 TW TW098119270A patent/TWI449703B/zh active
- 2009-06-09 RS RS20160062A patent/RS54560B1/en unknown
- 2009-06-09 UY UY0001031881A patent/UY31881A/es not_active Application Discontinuation
- 2009-06-09 PE PE2013001090A patent/PE20140407A1/es not_active Application Discontinuation
- 2009-06-09 US US12/481,028 patent/US8962629B2/en active Active
- 2009-06-09 JP JP2011513627A patent/JP5748659B2/ja active Active
- 2009-06-09 RU RU2015105591/04A patent/RU2015105591A/ru not_active Application Discontinuation
- 2009-06-09 CN CN2009801311819A patent/CN102118968A/zh active Pending
- 2009-06-09 BR BRPI0915374-8A patent/BRPI0915374B1/pt active IP Right Grant
- 2009-06-09 HU HUE09763424A patent/HUE028347T2/en unknown
- 2009-06-09 WO PCT/US2009/046714 patent/WO2009152133A1/en active Application Filing
- 2009-06-09 PL PL09763424T patent/PL2299821T3/pl unknown
- 2009-06-09 ES ES09763424.0T patent/ES2559403T3/es active Active
- 2009-06-09 PT PT97634240T patent/PT2299821E/pt unknown
- 2009-06-09 PE PE2010001126A patent/PE20110223A1/es active IP Right Grant
- 2009-06-09 RU RU2010153582/04A patent/RU2545023C9/ru active
- 2009-06-09 EP EP09763424.0A patent/EP2299821B1/en active Active
- 2009-06-09 DK DK09763424.0T patent/DK2299821T3/en active
- 2009-06-09 CN CN201410747767.0A patent/CN104592231A/zh active Pending
- 2009-06-09 KR KR1020117000497A patent/KR20110017431A/ko not_active IP Right Cessation
- 2009-06-09 ME MEP-2016-72A patent/ME02340B/me unknown
- 2009-06-09 CA CA3000973A patent/CA3000973A1/en not_active Abandoned
- 2009-06-09 UA UAA201100242A patent/UA106045C2/uk unknown
- 2009-06-09 NZ NZ623922A patent/NZ623922A/en unknown
- 2009-06-09 MY MYPI2010005827A patent/MY161369A/en unknown
- 2009-06-09 AU AU2009257602A patent/AU2009257602B2/en active Active
- 2009-06-09 KR KR1020167035162A patent/KR101718384B1/ko active IP Right Grant
- 2009-06-09 SI SI200931347T patent/SI2299821T1/sl unknown
- 2009-06-10 AR ARP090102084A patent/AR072086A1/es active IP Right Grant
-
2010
- 2010-11-18 IL IL209434A patent/IL209434A0/en active IP Right Grant
- 2010-11-29 CO CO10150402A patent/CO6382083A2/es not_active Application Discontinuation
- 2010-11-29 ZA ZA2010/08562A patent/ZA201008562B/en unknown
- 2010-12-02 NO NO20101688A patent/NO20101688A1/no not_active Application Discontinuation
- 2010-12-03 EC EC2010010657A patent/ECSP10010657A/es unknown
- 2010-12-08 DO DO2010000382A patent/DOP2010000382A/es unknown
- 2010-12-10 CL CL2010001426A patent/CL2010001426A1/es unknown
-
2011
- 2011-09-19 HK HK11109834.8A patent/HK1155617A1/zh unknown
-
2013
- 2013-03-08 DO DO2013000055A patent/DOP2013000055A/es unknown
-
2015
- 2015-01-30 US US14/610,119 patent/US9365579B2/en active Active
- 2015-05-11 JP JP2015096257A patent/JP2015163632A/ja active Pending
-
2016
- 2016-01-06 CR CR20160007A patent/CR20160007A/es unknown
- 2016-01-27 CY CY20161100074T patent/CY1117165T1/el unknown
- 2016-01-28 HR HRP20160098TT patent/HRP20160098T1/hr unknown
- 2016-05-12 US US15/152,823 patent/US20160326181A1/en not_active Abandoned
-
2017
- 2017-11-07 US US15/806,104 patent/US20180291029A1/en not_active Abandoned
-
2022
- 2022-01-14 US US17/575,731 patent/US20230082167A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
CR20120244A (es) | Inhibidores de la tirosina quinasa de bruton | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
EA200870409A1 (ru) | Антагонисты киназы pi3 | |
CL2011001215A1 (es) | Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes. | |
ECSP10010722A (es) | Compuestos orgánicos | |
EA200901157A1 (ru) | Конденсированные кольцевые гетероциклические модуляторы киназы | |
NO20084334L (no) | Farmasoytiske sammensetninger | |
CL2011001333A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
EA201170295A1 (ru) | ИНГИБИТОРЫ сМЕТ | |
CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. |